DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (Eton or the Company) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Enforcement Report - Week of November 15, 2023
Aurobindo's Generic Hydrocortisone Receives Approval in the U.S.
Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of February 22, 2023
Diurnal has announced that the first patient has been dosed in its phase 2 European clinical trial of modified-release hydrocortisone.
Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced that it has signed a distribution agreement with ExCEEd Orphan, a company providing full business solutions for the treatment of rare diseases, for the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsules) in Central and Eastern European (CEE) countries.
Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH).
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the commercial launch of Efmody® (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The launch of Efmody® follows its approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain (England, Wales and Scotland) in July 2021.